Generic semaglutide moves market
Apotex received tentative FDA approval for a generic version of semaglutide (Ozempic) in the U.S., while generic semaglutide flooding India has already forced Novo Nordisk to cut Ozempic and Wegovy prices by roughly 38% and 48% respectively. The twin developments show pricing pressure is arriving globally and could compress margins for incumbents. (prnewswire.com) (cnbc.com)
A diabetes drug that became a weight-loss blockbuster is now running into the oldest force in pharmaceuticals: cheaper copies. On April 10, Apotex said it won the first United States Food and Drug Administration tentative approval for a generic semaglutide injection, the active ingredient in Ozempic. (finance.yahoo.com) That word “tentative” is doing a lot of work. The United States Food and Drug Administration says the drug can meet the agency’s standards, but it still cannot be sold in the United States until patent or exclusivity barriers clear. (fda.gov) (business-standard.com) Semaglutide is the molecule behind Novo Nordisk’s Ozempic for diabetes and Wegovy for obesity. It belongs to a class called glucagon-like peptide-1 drugs, which mimic a gut hormone that helps control blood sugar and appetite. (cnbc.com) The United States is not where the price shock is happening first. In India, Novo Nordisk lost semaglutide patent protection in March 2026, and domestic drugmakers began launching lower-priced versions within days. (cnbc.com) At least five Indian companies entered immediately, and more than 50 brands were expected in the following months. Sun Pharmaceutical launched a weekly semaglutide injection starting at 750 rupees, or about $8, versus Novo’s earlier retail price of roughly 8,800 to 10,000 rupees depending on dose. (cnbc.com) Novo’s answer was not to walk away from India. It cut the starting price of Ozempic by 36% and Wegovy by 48%, bringing the base monthly price of both brands to 5,660 rupees from April 1. (economictimes.indiatimes.com) Those cuts still left room below Novo’s prices. Dr. Reddy’s priced one monthly semaglutide product at 4,200 rupees, Zydus averaged about 2,200 rupees per month, and some vial versions from Natco and Eris were priced as low as 1,290 rupees for a month’s supply. (economictimes.indiatimes.com) That is why the Apotex filing matters even before a single generic pen reaches an American pharmacy. India is showing what happens when semaglutide loses protection in a large market: dozens of manufacturers arrive, prices drop fast, and the brand owner cuts prices to defend share. (cnbc.com) (economictimes.indiatimes.com) Novo has already warned investors that 2026 sales could decline by 5% to 13%, and CNBC reported that patent expirations in India, Canada, Brazil, and China this year are likely to weigh on revenue. The United States remains protected much longer, with CNBC describing semaglutide there as protected from generic competition until 2032. (cnbc.com) So the market is now looking at semaglutide in two clocks at once. India is the live demo of what generic competition does to pricing today, and the United States tentative approval tells investors that the paperwork for the next phase is already being lined up. (finance.yahoo.com) (business-standard.com)
